TY - JOUR T1 - Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale JF - medRxiv DO - 10.1101/2020.07.30.20164939 SP - 2020.07.30.20164939 AU - Rachel Esra AU - Lise Jamieson AU - Matthew P. Fox AU - Daniel Letswalo AU - Nkosinathi Ngcobo AU - Sithabile Mngadi AU - Janne Estill AU - Gesine Meyer-Rath AU - Olivia Keiser Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/05/2020.07.30.20164939.abstract N2 - In the absence of a viable pharmaceutical intervention for SARS-CoV-2, governments have implemented a range of non-pharmaceutical interventions (NPIs) to curb the spread of infection of the virus and the disease caused by the virus, now known as COVID-19. Given the associated social and economic costs, it is critical to enumerate the individual impacts of NPIs to aid in decision-making moving forward. We used globally reported SARS-CoV-2 cases to fit a Bayesian model framework to estimate transmission associated with NPIs in 26 countries and 34 US states. Using a mixed effects model with country level random effects, we compared the relative impact of other NPIs to national-level household confinement measures and evaluated the impact of NPIs on the global trajectory of the COVID-19 pandemic over time. We observed heterogeneous impacts of the easing of restrictions and estimated an overall reduction in infection of 23% (95% CI: 18-27%) associated with household confinement, 10% (95% CI: 1-18%) with limits on gatherings, 12% (95% CI: 5-19%) with school closures and 17% (95% CI: 6-28%) with mask policies. We estimated a 12% (95% CI: 9-15%) reduction in transmission associated with NPIs overall. The implementation of NPIs have substantially reduced acceleration of COVID-19. At this early time point, we cannot determine the impact of the easing of restrictions and there is a need for continual assessment of context specific effectiveness of NPIs as more data become available.Competing Interest StatementThe authors have declared no competing interest.Funding StatementRole of the funding source: Rachel Esra is supported in part by the European Union's Horizon 2020 research and innovation programme and the Swiss Excellence Foreign Scholar Grant. Olivia Keiser is supported by the Swiss National Science Foundation Grants 163878 and 196270.This study has additionally been made possible by the generous support of the American People and the President's Emergency Plan for AIDS Relief (PEPFAR) through USAID under the terms of Cooperative Agreement 72067419CA00004 to HE2RO. The contents are the responsibility of the authors and do not necessarily reflect the views of PEPFAR, USAID or the United States Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research did not involve human or animal subjects, and ethical approval was therefore not requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource code is available at https://github.com/epiforecasts/covid, unless otherwise noted. https://gitlab.com/igh-idmm-public/covid-19/covid19_npi_globalrt_estimations ER -